Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Research ArticleGroup for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2017 Annual Meeting Amsterdam, the Netherlands

The Microbiome in Psoriasis and Psoriatic Arthritis: Joints

Jose U. Scher
The Journal of Rheumatology Supplement June 2018, 94 32-35; DOI: https://doi.org/10.3899/jrheum.180134
Jose U. Scher
From the Psoriatic Arthritis Center, Division of Rheumatology, New York University Langone Health; Microbiome Center for Rheumatology and Autoimmunity (MiCRA), Division of Rheumatology, New York University School of Medicine and Hospital for Joint Diseases, New York, New York, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Jose.Scher@nyumc.org
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

The microbiome is a known and established immunomodulator of many inflammatory disorders, including psoriasis and psoriatic arthritis. Microbes co-evolved with their human hosts and provide them with nutritional, metabolic, and immunologic support. An accumulating body of evidence has revealed that psoriatic diseases are characterized by a state of intestinal dysbiosis, which has been linked to a decrease in beneficial commensals and fatty acids. This has been shown in both animal models and human samples, and multiple studies have addressed the physiological and potentially pathogenic role of intestinal and cutaneous microbes in human health and disease. In this review, we discuss state-of-the-art literature in the field of the microbiome in psoriatic diseases that was presented during the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2017 annual meeting, with a special emphasis on synovio-entheseal inflammation. A better understanding of these microbe-host interactions can lead to novel diagnostic and therapeutic targets.

Key Indexing Terms:
  • PSORIATIC ARTHRITIS
  • GRAPPA
  • PSORIASIS
  • MICROBIOME
  • JOINTS
  • SPONDYLOARTHRITIS

For millennia, microbes have co-evolved with their human hosts, populating most mucosal sites. These microorganisms are fundamental to their host’s physiology and help maintain immune and metabolic homeostasis. An accumulating body of literature has established the mechanisms that underlie the crosstalk between the microbiome-mucosal interface and the downstream host immune response. However, the precise molecular signaling that directs this microbial influence in disease pathogenesis is emerging and continues to be a central research area in the fields of inflammation, oncology, and autoimmunity.

Joshua Lederberg defined and described the microbiome as “the ecological communities of commensal, symbiotic, and pathogenic microorganisms (including their genes) that literally share our body space”1. While adults carry 2–3 pounds of bacteria at any given moment, the genes within the human microbiome astoundingly outnumber the host’s genetic contribution 100-fold2. These populations, with niche-specific characteristics, inhabit the upper and lower respiratory tract, skin, upper gastrointestinal tract, and female genital tract. However, the largest proportion of human microorganisms resides in the lower gastrointestinal tract, which is home to hundreds of bacterial, viral, and fungal species that form a complex and dynamic ecosystem3.

The microbial colonization of the gut begins at birth with vaginal- or cutaneous-derived bacteria, depending on delivery mode4. These populations vary significantly, and the intestine’s final composition depends on many factors, including host genetics, milk and food types, maternal microbiota, and exposure to antibiotics and other insults5.

After the first year of life (when solid food is introduced), the human microbiome begins to maintain its overall structure over time and becomes robust and resilient2,6. However, when this equilibrium is perturbed, a dysbiotic process can serve as a triggering factor for the initiation and perpetuation of many inflammatory arthritides, including rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA)7. This process has been studied and validated over the last 2 decades in animal models of these disorders, where specific perturbations in the microbiome’s composition can result in downstream inflammatory events at mucosal surfaces, ultimately leading to systemic disease in susceptible hosts5. Multiple cells residing in the intestinal lamina propria appear to be important in translating dysbiosis into local and distal proinflammatory programs, including dendritic cells, Th17 cells, plasma cells, innate lymphoid cells, γ-δ T cells, and several others8. Several mechanisms have been proposed through which microbiome community perturbations may direct the immune response, including altered epithelial and mucosal permeability, loss of immune tolerance to components of commensals, and trafficking of effector immune cells into the synovium.

Intestinal Microbiome in PsA and SpA: From Models to Humans

The clinical and biological connection between SpA, PsA, and gut inflammation is well established. As a group, SpA-spectrum diseases share a genetic predisposition (i.e., HLA-B27); effector immune cells in their pathogenesis (Th17 cells and other type-17 cells); and clinical manifestations around peripheral and axial arthritis, psoriasis, and intestinal inflammation. The reason certain specific phenotypes are expressed in particular individuals at the expense of other phenotypes has remained one of the leading enigmas in the field. What is more certain is the well-established connection between the development of synovio-entheseal inflammation and psoriasis in the context of clinical (and subclinical) gut inflammation (and vice versa). This is best exemplified by the so-called “enteroarthropathies,” in which intestinal infectious agents trigger distal disease.

This is indeed the case in reactive arthritis (ReA), where bacterial gut pathogens cause joint inflammation in genetically predisposed patients9. Moreover, about 20% of patients with ReA go on to develop ankylosing spondylitis (AS). A similar pattern of gut-joint axis pathology is evidenced in Whipple disease and jejunoileal bypass arthritis10,11. Intriguingly, over 50% of patients with SpA and PsA have subclinical gut inflammation, supporting the involvement of mucosal inflammation in the pathogenesis of these diseases12,13.

Similarly, there is an intimate and reciprocal connection between gut and joint inflammation in inflammatory bowel disease (IBD), in which peripheral arthritis occurs in up to 25% of patients14. Spine involvement, particularly asymptomatic sacroiliitis, is even more frequent, with fully manifested AS developing in up to 1 in 10 patients with IBD.

Animal models of SpA and PsA (i.e., HLA-B27 transgenic rats and SKG mice) do not develop SpA-like disease when raised under germ-free conditions (cages voided of microorganisms). It is only when exposed to specific members of the enteric community that these animals develop the phenotype (peripheral arthritis, SpA, psoriasiform skin disease, and Crohn-like ileitis), supporting the hypothesis that gut microbiota is indeed necessary for the initiation of disease15,16. However, the mechanism by which this occurs is still a matter of intense research. Certainly, the role of Type-17 cells and the interleukin (IL)-23/IL-17 axis appears to play a central role17,18,19 because these cells are essential in the initiation and maintenance of gut inflammation in IBD20. Similarly, the high expression of IL-17 can be found in the synovial fluids of SpA, while increased circulating Th17 cells have also been reported21.

To date, there have been few comprehensive studies of intestinal inflammation characterization in humans with SpA spectrum disease and PsA. Classic work by Mielants, et al initially found an increased intestinal permeability in patients with RA, SpA, and IBD22. More recent, Ciccia, et al found that more than half of patients with PsA have subclinical gut inflammation and increased levels of Th17 as well as Th9 cells23. Similarly, only a handful of studies have characterized the link between PsA and the microbiome. Two studies have assessed the cutaneous microbiota composition in patients with psoriasis, with somehow divergent findings. However, both Gao, et al and Fahlén, et al found that psoriatic plaques have a significantly lower abundance of Propionibacterium spp.24,25. This is of interest because PsA develops in up to one-third of patients with psoriasis, making the skin microbiome a potential biomarker (and target) for the development of synovio-entheseal inflammation.

Our group described the intestinal microbiome in both patients with psoriasis and PsA compared to healthy controls and found that, while both psoriasis and PsA groups showed decreased abundance of the Coprococcus genus compared to healthy controls, the PsA group was further characterized by significantly lower levels of the Akkermansia and Ruminococcus genera. This suggests a continuum in the loss of diversity that may potentially correlate with the natural history of disease26. Curiously, studies in IBD also implicate these genera, with a decreased abundance of Ruminococcus and Akkermansia in both ulcerative colitis and Crohn disease27. Further, we found that this intestinal dysbiosis in patients with PsA correlates with decreased levels of medium-chain fatty acids (MCFA) in the intestinal luminal content, which are known to be beneficial for the maintenance of gut epithelial health28. These may also represent potentially modifiable biological factors in the progression from psoriasis to PsA26. Although this is still a nascent field, recent work on human SpA29, IBD-arthritis30, and ReA31 points toward a common gut dysbiotic process that underlies these inflammatory arthritides.

Strategies to Restore Intestinal Homeostasis

There are multiple potential ways to alter the intestinal microbial community in an attempt to restore gut health and downstream immune responses in psoriatic disease. The strategies range from dietary habit changes to modifying the bioactive molecules that are produced by bacterial strains. Although there is some evidence for a potential clinical benefit of weight loss in psoriasis and PsA32,33, the data remain nonexistent for microbial ecosystem therapeutics through fecal microbiota transplant. This is not the case in IBD, where many studies have shown significant positive results in the treatment of colitis34,35,36, supporting an argument that these interventions could at least theoretically be applied to the treatment of psoriatic disease.

The involvement of the microbiome in humans has been studied for several decades and is familiar to the rheumatology community. The advent of large, parallel sequencing technologies and dramatic advances in the understanding of mucosal immunology have provided a more precise knowledge of the microbe-host cross-talk in physiology and inflammatory disease. How and why microorganisms and their components influence immune homeostasis and the downstream activation of proinflammatory events in autoimmunity is a matter of intense research. Similarly, the application of this basic knowledge in the clinical setting and as potential therapeutic targets is offering new opportunities for the treatment and prevention of psoriatic disease and related conditions.

Footnotes

  • As part of the supplement series GRAPPA 2017, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards.

  • Source of support: Grants No. K23AR064318 and R03AR072182 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases to Dr. Scher; The Colton Center for Autoimmunity; The Riley Family Foundation; and The Beatriz Snyder Foundation.

REFERENCES

  1. 1.↵
    1. Lederberg J
    . Infectious history. Science 2000;288:287–93.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Ley RE,
    2. Lozupone CA,
    3. Hamady M,
    4. Knight R,
    5. Gordon JI
    . Worlds within worlds: evolution of the vertebrate gut microbiota. Nat Rev Microbiol 2008;6:776–88.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Human Microbiome Jumpstart Reference Strains Consortium,
    2. Nelson KE,
    3. Weinstock GM,
    4. Highlander SK,
    5. Worley KC,
    6. Creasy HH,
    7. Wortman JR,
    8. et al.
    A catalog of reference genomes from the human microbiome. Science 2010;328:994–9.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Dominguez-Bello MG,
    2. Costello EK,
    3. Contreras M,
    4. Magris M,
    5. Hidalgo G,
    6. Fierer N,
    7. et al.
    Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A 2010;107:11971–5.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Yeoh N,
    2. Burton JP,
    3. Suppiah P,
    4. Reid G,
    5. Stebbings S
    . The role of the microbiome in rheumatic diseases. Curr Rheumatol Rep 2013;15:314.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Koenig JE,
    2. Spor A,
    3. Scalfone N,
    4. Fricker AD,
    5. Stombaugh J,
    6. Knight R,
    7. et al.
    Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci U S A 2011;108 Suppl 1:4578–85.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Scher JU,
    2. Littman DR,
    3. Abramson SB
    . Microbiome in inflammatory arthritis and human rheumatic diseases. Arthritis Rheumatol 2016;68:35–45.
    OpenUrlCrossRef
  8. 8.↵
    1. Honda K,
    2. Littman DR
    . The microbiome in infectious disease and inflammation. Annu Rev Immunol 2012;30:759–95.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Carter JD,
    2. Hudson AP
    . Reactive arthritis: clinical aspects and medical management. Rheum Dis Clin North Am 2009;35:21–44.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Moos V,
    2. Schneider T
    . Changing paradigms in Whipple’s disease and infection with Tropheryma whipplei. Eur J Clin Microbiol Infect Dis 2011;30:1151–8.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Ross CB,
    2. Scott HW,
    3. Pincus T
    . Jejunoileal bypass arthritis. Baillieres Clin Rheumatol 1989;3:339–55.
    OpenUrlPubMed
  12. 12.↵
    1. Mielants H,
    2. Veys EM,
    3. De Vos M,
    4. Cuvelier C,
    5. Goemaere S,
    6. De Clercq L,
    7. et al.
    The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol 1995;22:2266–72.
    OpenUrlPubMed
  13. 13.↵
    1. Manasson J,
    2. Scher JU
    . Spondyloarthritis and the microbiome: new insights from an ancient hypothesis. Curr Rheumatol Rep 2015;17:10.
    OpenUrl
  14. 14.↵
    1. Arvikar SL,
    2. Fisher MC
    . Inflammatory bowel disease associated arthropathy. Curr Rev Musculoskelet Med 2011;4:123–31.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Rath HC,
    2. Herfarth HH,
    3. Ikeda JS,
    4. Grenther WB,
    5. Hamm TE Jr,
    6. Balish E,
    7. et al.
    Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996;98:945–53.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Hammer RE,
    2. Maika SD,
    3. Richardson JA,
    4. Tang JP,
    5. Taurog JD
    . Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 1990;63:1099–112.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Yoshitomi H,
    2. Sakaguchi N,
    3. Kobayashi K,
    4. Brown GD,
    5. Tagami T,
    6. Sakihama T,
    7. et al.
    A role for fungal {beta}-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. J Exp Med 2005;201:949–60.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Benham H,
    2. Rehaume LM,
    3. Hasnain SZ,
    4. Velasco J,
    5. Baillet AC,
    6. Ruutu M,
    7. et al.
    Interleukin-23 mediates the intestinal response to microbial β-1,3-glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol 2014;66:1755–67.
    OpenUrl
  19. 19.↵
    1. Rehaume LM,
    2. Mondot S,
    3. Aguirre de Carcer D,
    4. Velasco J,
    5. Benham H,
    6. Hasnain SZ,
    7. et al.
    ZAP-70 genotype disrupts the relationship between microbiota and host, leading to spondyloarthritis and ileitis in SKG mice. Arthritis Rheumatol 2014;66:2780–92.
    OpenUrl
  20. 20.↵
    1. Seiderer J,
    2. Elben I,
    3. Diegelmann J,
    4. Glas J,
    5. Stallhofer J,
    6. Tillack C,
    7. et al.
    Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn’s disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis 2008;14:437–45.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Appel H,
    2. Maier R,
    3. Wu P,
    4. Scheer R,
    5. Hempfing A,
    6. Kayser R,
    7. et al.
    Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011;13:R95.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Mielants H,
    2. Veys EM,
    3. De Vos M,
    4. Cuvelier C
    . Increased intestinal permeability in ankylosing spondylitis. Gut 1992;33:1150.
    OpenUrlFREE Full Text
  23. 23.↵
    1. Ciccia F,
    2. Guggino G,
    3. Ferrante A,
    4. Raimondo S,
    5. Bignone R,
    6. Rodolico V,
    7. et al.
    Interleukin-9 overexpression and Th9 polarization characterize the inflamed gut, the synovial tissue, and the peripheral blood of patients with psoriatic arthritis. Arthritis Rheumatol 2016;68:1922–31.
    OpenUrl
  24. 24.↵
    1. Gao Z,
    2. Tseng CH,
    3. Strober BE,
    4. Pei Z,
    5. Blaser MJ
    . Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PLoS One 2008;3:e2719.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Fahlén A,
    2. Engstrand L,
    3. Baker BS,
    4. Powles A,
    5. Fry L
    . Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skin. Arch Dermatol Res 2012;304:15–22.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Scher JU,
    2. Ubeda C,
    3. Artacho A,
    4. Attur M,
    5. Isaac S,
    6. Reddy SM,
    7. et al.
    Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol 2015;67:128–39.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Png CW,
    2. Linden SK,
    3. Gilshenan KS,
    4. Zoetendal EG,
    5. McSweeney CS,
    6. Sly LI,
    7. et al.
    Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol 2010;105:2420–8.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Anbazhagan AN,
    2. Priyamvada S,
    3. Gujral T,
    4. Bhattacharyya S,
    5. Alrefai WA,
    6. Dudeja PK,
    7. et al.
    A novel anti-inflammatory role of GPR120 in intestinal epithelial cells. Am J Physiol Cell Physiol 2016;310:C612–21.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Tito RY,
    2. Cypers H,
    3. Joossens M,
    4. Varkas G,
    5. Van Praet L,
    6. Glorieus E,
    7. et al.
    Brief report: dialister as a microbial marker of disease activity in spondyloarthritis. Arthritis Rheumatol 2017;69:114–21.
    OpenUrl
  30. 30.↵
    1. Viladomiu M,
    2. Kivolowitz C,
    3. Abdulhamid A,
    4. Dogan B,
    5. Victorio D,
    6. Castellanos JG,
    7. et al.
    IgA-coated E. coli enriched in Crohn’s disease spondyloarthritis promote TH17-dependent inflammation. Sci Transl Med 2017;9.(376)
  31. 31.↵
    1. Manasson J,
    2. Shen N,
    3. Garcia Ferrer HR,
    4. Ubeda C,
    5. Iraheta I,
    6. Heguy A,
    7. et al.
    Gut microbiota perturbations in reactive arthritis and post-infectious spondyloarthritis. Arthritis Rheumatol 2018;70:242–54.
    OpenUrl
  32. 32.↵
    1. Eder L,
    2. Thavaneswaran A,
    3. Chandran V,
    4. Cook RJ,
    5. Gladman DD
    . Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis 2015;74:813–7.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. di Minno MN,
    2. Peluso R,
    3. Iervolino S,
    4. Lupoli R,
    5. Russolillo A,
    6. Scarpa R,
    7. et al.
    Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res 2013;65:141–7.
    OpenUrlCrossRef
  34. 34.↵
    1. Borody TJ,
    2. Warren EF,
    3. Leis S,
    4. Surace R,
    5. Ashman O
    . Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003;37:42–7.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Kelly CR,
    2. Khoruts A,
    3. Staley C,
    4. Sadowsky MJ,
    5. Abd M,
    6. Alani M,
    7. et al.
    Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med 2016;165:609–16.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Moayyedi P,
    2. Surette MG,
    3. Kim PT,
    4. Libertucci J,
    5. Wolfe M,
    6. Onischi C,
    7. et al.
    Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015;149:102–9.e6.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology Supplement
Vol. 94
1 Jun 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Microbiome in Psoriasis and Psoriatic Arthritis: Joints
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Microbiome in Psoriasis and Psoriatic Arthritis: Joints
Jose U. Scher
The Journal of Rheumatology Supplement Jun 2018, 94 32-35; DOI: 10.3899/jrheum.180134

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
The Microbiome in Psoriasis and Psoriatic Arthritis: Joints
Jose U. Scher
The Journal of Rheumatology Supplement Jun 2018, 94 32-35; DOI: 10.3899/jrheum.180134
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • Abstract
    • Intestinal Microbiome in PsA and SpA: From Models to Humans
    • Strategies to Restore Intestinal Homeostasis
    • Footnotes
    • REFERENCES
  • References
  • Info & Metrics
  • PDF
  • eLetters

Keywords

PSORIATIC ARTHRITIS
GRAPPA
PSORIASIS
MICROBIOME
JOINTS
SPONDYLOARTHRITIS

Related Articles

Cited By...

More in this TOC Section

  • The Patient Research Partner Network Matures: A Report from the GRAPPA 2017 Annual Meeting
  • Prologue: 2017 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
  • GRAPPA 2017 Project Report
Show more Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2017 Annual Meeting Amsterdam, the Netherlands

Similar Articles

Keywords

  • psoriatic arthritis
  • GRAPPA
  • psoriasis
  • MICROBIOME
  • JOINTS
  • spondyloarthritis

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire